Physician profile
Amanda Holsworth
NPI 1811336506
$2,289.23
in general payments reported to CMS, 2019-2025
21 companies · $589 in 2025
The $589 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2021: $144 · 2022: $128 · 2023: $392 · 2024: $513 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,453 · Education: $41.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,452.66 |
| Education | $41.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $518.26 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $263.44 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $181.71 | 2021-2025 | Fasenra, Tezspire |
| Novartis Pharmaceuticals Corporation | $165.56 | 2024-2025 | |
| Pharming Healthcare, INC. | $129.61 | 2023-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $128.42 | 2022-2025 | Hyqvia, Eohilia |
| Shire North American Group INC | $124.99 | 2019 | |
| Lilly USA, LLC | $93.00 | 2024-2025 | Ebglyss |
| Grifols USA, LLC | $92.28 | 2019-2023 | Prolastin-C Liquid, Xembify |
| Ars Pharmaceuticals Operations, INC. | $90.34 | 2025 | Neffy |
| Pfizer INC. | $83.19 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $73.62 | 2022-2024 | Orladeyo |
| Genzyme Corporation | $64.79 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $49.18 | 2022-2024 | |
| Genentech USA, INC. | $43.95 | 2024-2025 | Xolair |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $41.64 | 2022-2023 | Hizentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.58 | 2023-2024 | Spiriva Respimat |
| Alk-Abello, INC | $32.22 | 2023 | Grastek, Odactra, Ragwitek |
| Amgen INC. | $30.04 | 2023-2024 | Tezspire |
| Horizon Therapeutics Plc | $29.41 | 2019-2022 | |
| Ucb, INC. | $18.00 | 2024 | Cimzia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Holsworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.